Closing the production gap in gene therapy – A scalable helper virus-free AAV production platformPublished: August 13, 2019
With gene therapy projects moving towards more common diseases, such as Rheumatoid Arthritis, Parkinson´s disease or Alzheimer´s disease, there is a growing need for large-scale viral vector production, in particular for adeno-associated viral (AAV) vectors. However, current production systems rely on transient plasmid transfection or helper viruses and are thus hardly scalable. The webinar will address solutions to overcome this production gap in gene therapy.
Watch this On Demand Webinar with Dr Nicole Faust, CEO & CSO at CEVEC, Dr Clive Glover, Director of Strategy at Pall, Dr Andy Topping, Chief Scientific Officer at FUJIFILM Diosynth Biotechnologies and Dr Philip Wills, Chief Commercial Officer at Paragon Bioservices as you learn how CEVEC´s stable, helper virus-free AAV platform overcomes scalability issues by moving AAV production to stable producer cells.
Dr Nicole Faust, CEO & CSO, CEVEC
Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.
Dr Clive Glover, Director, Strategy, Pall Corporation
Dr Clive Glover is the Director, Strategy at Pall Corporation where he leads Pall’s cell and gene therapy business. Previously he was responsible for driving product development efforts around cell therapy at GE Healthcare and has also held positions in marketing and product management at STEMCELL Technologies. Clive holds a PhD in Genetics from the University of British Columbia.
Dr Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies
Dr Topping is a seasoned professional in the biopharmaceutical industry with a career that spans over 25 years. As CSO, Andy brings in the depth and breadth of knowledge built over tenure at Fujifilm Diosynth Biotechnologies where he has served a variety of scientific roles. In his most recent position as Director of Development his focus has been on working with customers to develop innovative and scientifically sound solutions to programs. Dr. Topping also oversees all of the Innovation Initiatives at Fujifilm Diosynth Biotechnologies. He received his Ph.D. from the University of Wales at Cardiff.
Dr Philip Wills, Chief Commercial Officer, Paragon Bioservices, Inc
Philip is a seasoned executive and scientist with over 15 years of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He has been with Paragon since 2002 and is heavily involved in Paragon’s corporate strategy. Prior to his current position as Chief Commercial Officer, Philip was the VP of Business Development and Principle Scientist at Paragon. Preceding to that role, Philip has held positions as the Corporate Scientific Liaison as well as the Group Leader for Paragon’s Analytical Department. Philip started his career at the University of Maryland and worked in a variety of scientific roles in both the School of Medicine and Cancer Center. Philip obtained a BA in Chemistry from The Johns Hopkins University and a Ph.D. in Pharmacology from the University of Maryland Medical School.